Ophelia Rogers

1.6k total citations
33 papers, 1.2k citations indexed

About

Ophelia Rogers is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Ophelia Rogers has authored 33 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 17 papers in Hematology and 11 papers in Molecular Biology. Recurrent topics in Ophelia Rogers's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers), Acute Myeloid Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (8 papers). Ophelia Rogers is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers), Acute Myeloid Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (8 papers). Ophelia Rogers collaborates with scholars based in United States. Ophelia Rogers's co-authors include Martin D. Snider, Alison R. Moliterno, Jerry L. Spivak, Donna M. Williams, Mathias Oelke, Tonya J. Webb, Robert Giuntoli, Robert E. Bristow, Alessia Zoso and Teresa Díaz-Montes and has published in prestigious journals such as New England Journal of Medicine, Cell and The Journal of Cell Biology.

In The Last Decade

Ophelia Rogers

31 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ophelia Rogers United States 14 697 503 397 216 197 33 1.2k
Artur Słupianek United States 23 1.2k 1.8× 602 1.2× 986 2.5× 262 1.2× 192 1.0× 48 2.2k
Lolita Banerji United Kingdom 13 753 1.1× 211 0.4× 264 0.7× 77 0.4× 215 1.1× 15 1.1k
Christine Tran Quang France 12 620 0.9× 269 0.5× 403 1.0× 75 0.3× 289 1.5× 21 1.3k
Margaret Nieborowska-Skorska United States 23 1.1k 1.5× 705 1.4× 1.2k 3.0× 300 1.4× 137 0.7× 54 2.1k
David Wisniewski United States 22 859 1.2× 435 0.9× 697 1.8× 203 0.9× 308 1.6× 44 1.6k
Andrea Hoelbl‐Kovacic Austria 17 481 0.7× 345 0.7× 474 1.2× 105 0.5× 306 1.6× 24 1.2k
M. Golam Mohi United States 12 1.2k 1.7× 475 0.9× 588 1.5× 179 0.8× 586 3.0× 16 1.6k
Frank Breitenbuecher Germany 18 728 1.0× 393 0.8× 811 2.0× 56 0.3× 114 0.6× 33 1.5k
Ulrike Huffstadt Germany 5 361 0.5× 217 0.4× 169 0.4× 95 0.4× 218 1.1× 7 850
Vadym Zaberezhnyy United States 16 704 1.0× 114 0.2× 351 0.9× 49 0.2× 160 0.8× 25 1.1k

Countries citing papers authored by Ophelia Rogers

Since Specialization
Citations

This map shows the geographic impact of Ophelia Rogers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ophelia Rogers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ophelia Rogers more than expected).

Fields of papers citing papers by Ophelia Rogers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ophelia Rogers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ophelia Rogers. The network helps show where Ophelia Rogers may publish in the future.

Co-authorship network of co-authors of Ophelia Rogers

This figure shows the co-authorship network connecting the top 25 collaborators of Ophelia Rogers. A scholar is included among the top collaborators of Ophelia Rogers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ophelia Rogers. Ophelia Rogers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spivak, Jerry L., Akil Merchant, Donna M. Williams, et al.. (2020). Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS ONE. 15(6). e0232801–e0232801. 10 indexed citations
2.
Borodovsky, Anna, Wendell Davis, Kristina Yucius, et al.. (2018). Development of Liver-Specific Thrombopoietin Targeted Sirnas: Impact on Platelet Count, Megakaryocyte Mass, and Hematopoietic Progenitors in Normal and MPN Murine Models. Blood. 132(Supplement 1). 4329–4329. 2 indexed citations
3.
Spivak, Jerry L., Michael Considine, Donna M. Williams, et al.. (2014). Two Clinical Phenotypes in Polycythemia Vera. New England Journal of Medicine. 371(9). 808–817. 47 indexed citations
4.
Spivak, Jerry L., Akil Merchant, Donna M. Williams, et al.. (2012). A Functional Thrombopoietin Receptor Is Required for Full Expression of Phenotype in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera. Blood. 120(21). 427–427. 4 indexed citations
5.
6.
Gerber, Jonathan M., Hao Zhang, Donna M. Williams, et al.. (2011). The Leukemic Stem Cell in Polycythemia Vera and Primary Myelofibrosis Is Distinct From the Initiating JAK2 V617F-Positive Hematopoiertic Stem Cell. Blood. 118(21). 613–613. 2 indexed citations
7.
8.
Stein, Barry, Donna M. Williams, Nae‐Yuh Wang, et al.. (2010). Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders. Haematologica. 95(7). 1090–1097. 75 indexed citations
9.
Giuntoli, Robert, Tonya J. Webb, Alessia Zoso, et al.. (2009). Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.. PubMed. 29(8). 2875–84. 157 indexed citations
10.
Webb, Tonya J., Robert Giuntoli, Ophelia Rogers, Jonathan P. Schneck, & Mathias Oelke. (2008). Ascites Specific Inhibition of CD1d-Mediated Activation of Natural Killer T Cells. Clinical Cancer Research. 14(23). 7652–7658. 18 indexed citations
11.
Moliterno, Alison R., et al.. (2008). Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens. Experimental Hematology. 36(11). 1480–1486.e2. 73 indexed citations
12.
Williams, Donna M., et al.. (2007). Phenotypic variations and new mutations in JAK2 V617F–negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Experimental Hematology. 35(11). 1641–1646. 61 indexed citations
13.
Moliterno, Alison R., Donna M. Williams, Ophelia Rogers, & Jerry L. Spivak. (2006). Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 108(12). 3913–3915. 87 indexed citations
14.
Pemmaraju, Naveen, Alison R. Moliterno, Donna M. Williams, Ophelia Rogers, & Jerry L. Spivak. (2006). Heterogeneous JAK2V617F Allele Burden in Essential Thrombocytosis: Gender and Clinical Correlates.. Blood. 108(11). 2679–2679. 2 indexed citations
15.
Moliterno, Alison R., et al.. (2006). Disease Burden in the Chronic Myeloproliferative Disorders Correlates with the Stem Level of JAK2 V617F Expression.. Blood. 108(11). 668–668. 1 indexed citations
16.
Moliterno, Alison R., Donna M. Williams, Ophelia Rogers, & Jerry L. Spivak. (2005). Molecular Mimicry in the Chronic Myeloproliferative Disorders: Reciprocity between JAK2 V617F Genotype and Mpl Expression.. Blood. 106(11). 3520–3520. 1 indexed citations
17.
18.
Rogers, Ophelia, et al.. (1989). Erythropoietin receptors on murine erythroid colony-forming units: natural history. Blood. 73(6). 1476–1486. 65 indexed citations
19.
Snider, Martin D. & Ophelia Rogers. (1986). Membrane traffic in animal cells: cellular glycoproteins return to the site of Golgi mannosidase I.. The Journal of Cell Biology. 103(1). 265–275. 81 indexed citations
20.
Snider, Martin D. & Ophelia Rogers. (1985). Intracellular movement of cell surface receptors after endocytosis: resialylation of asialo-transferrin receptor in human erythroleukemia cells.. The Journal of Cell Biology. 100(3). 826–834. 195 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Artur Słupianek Breakdown of academic impact, for papers by Lolita Banerji Breakdown of academic impact, for papers by Christine Tran Quang Breakdown of academic impact, for papers by Margaret Nieborowska-Skorska Breakdown of academic impact, for papers by David Wisniewski Breakdown of academic impact, for papers by Andrea Hoelbl‐Kovacic Breakdown of academic impact, for papers by M. Golam Mohi Breakdown of academic impact, for papers by Frank Breitenbuecher Breakdown of academic impact, for papers by Ulrike Huffstadt Breakdown of academic impact, for papers by Vadym Zaberezhnyy
Rankless by CCL
2026